BrainsWay Completes Revenue-Based Milestone Investment into Axis Integrated Mental Health
MWN-AI** Summary
BrainsWay Ltd., a leader in noninvasive neurostimulation for mental health disorders, has successfully completed a $1 million milestone-based investment in Axis Integrated Mental Health, a management services organization supporting mental health clinics in Colorado. This investment follows Axis’s accomplishment of a revenue performance target set in a strategic equity financing agreement established in August 2025. BrainsWay initially invested $2.3 million in Axis, recognizing the organization's effective execution of its growth strategy and rapid achievement of the revenue milestone.
Hadar Levy, CEO of BrainsWay, expressed enthusiasm for Axis’s early success, indicating that the venture illustrates the company's focus on identifying and supporting scalable networks capable of driving growth and improving access to mental health treatment. Chris Perez, CEO of Axis, echoed this sentiment, celebrating the partnership with BrainsWay as an essential element of their growth strategy and commitment to advanced mental health treatments.
Under the agreement, BrainsWay maintains a minority equity stake in Axis through a preferred, annually compounding security, which includes specific redemption rights relating to the shares. This strategic investment aims to enhance the integration of advanced therapeutic approaches, including BrainsWay’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™), which has gained FDA clearance for several indications including major depressive disorder, obsessive-compulsive disorder, and smoking addiction.
With operations across the U.S. and Israel, BrainsWay remains dedicated to advancing neuroscience through innovative treatments backed by robust clinical evidence. Meanwhile, Axis focuses on providing a holistic, integrative approach to mental health care, combining modern therapies under a single coordinated experience. This collaboration reflects both organizations' commitment to improving mental health care access and efficacy.
MWN-AI** Analysis
BrainsWay Ltd. (NASDAQ: BWAY), a pioneer in advanced neurostimulation treatments for mental health disorders, has made a strategic milestone-based investment of $1 million into Axis Integrated Mental Health. This investment, following Axis's successful revenue performance, highlights the promising growth trajectory of both companies in the mental health space.
Investors should consider this partnership as a significant positive signal. BrainsWay’s decision to invest further demonstrates confidence in Axis's business model, particularly in a market increasingly focused on innovative mental health solutions. Axis's approach to integrating advanced treatments, including BrainsWay's Deep TMS, with traditional psychiatric practices positions it favorably within the mental health services sector, one that is critically underserved but rapidly expanding.
The investment strategy is particularly noteworthy. BrainsWay retains a minority interest in Axis through a preferred, annually compounding security, providing stability and potential returns linked to Axis's financial growth. The partnership allows BrainsWay to leverage its proprietary Deep TMS technology, which has gained FDA clearance for multiple indications, providing a competitive edge as the demand for effective mental health treatments grows.
However, potential investors should remain aware of inherent risks, including regulatory approvals, market acceptance of Deep TMS technology, and competition. Given the historical volatility in biotech stocks, it’s wise to approach investments in BrainsWay with a careful assessment of market conditions and company performance metrics.
In summary, BrainsWay's commitment to Axis reflects a robust growth strategy and confidence in advanced treatment modalities. This partnership could enhance BrainsWay's market position and appeal to investors looking for growth opportunities within the mental health sector, provided they remain mindful of the associated risks.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
BURLINGTON, Mass. and JERUSALEM, March 19, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it has completed a $1 million milestone-based investment in Axis Management Company, Inc. (“Axis Integrated Mental Health” or “Axis”), a management services organization servicing several mental health clinics in Colorado. The investment was made following Axis’s achievement of a predefined revenue performance milestone under the terms of the two companies’ August 2025 strategic equity financing agreement.
“We are excited for the Axis team and their early success in executing a successful growth strategy since our original $2.3 million equity investment. Their rapid achievement of the revenue milestone underscores this program’s ability to identify strong networks such as Axis that can deploy capital effectively to drive growth within the market and increase access to care,” said Hadar Levy, Chief Executive Officer of BrainsWay.
“This is an exciting time for the Axis team, as we continue to meet the goals we set for our growth strategy. The partnership with BrainsWay continues to be a major part of that strategy and is grounded in our shared commitment to delivering the most advanced mental health treatments to the communities we serve,” stated Chris Perez, Chief Executive Officer of Axis.
Under the terms of the agreement, BrainsWay holds a minority position in Axis in the form of a preferred, annually compounding security. The agreement also provides for a redemption mechanism relating to the shares.
About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in the United States and Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.
About Axis
Axis Integrated Mental Health services its leading mental health practices, which are dedicated to transforming lives through a truly comprehensive, integrative model of care. With a team of board-certified specialists combining modern psychiatry and psychotherapy with advanced treatments including Deep TMS™ and Spravato®, Axis utilizes an evidence-based, holistic therapeutic approach to treat patients, all through a single, coordinated care experience under one roof.
For more information, please visit axismh.com.
Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words, and also includes any financial guidance and projections contained herein. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the failure of our investments in management services organizations and/or other clinic-related entities to produce profitable returns; inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company’s anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company’s intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements.
Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission.
Contacts:
BrainsWay:
Ido Marom
Chief Financial Officer
Ido.Marom@BrainsWay.com
Investors:
Brian Ritchie
LifeSci Advisors LLC
britchie@lifesciadvisors.com
FAQ**
How does Brainsway Ltd Ord BRSYF plan to leverage its minority position in Axis Integrated Mental Health to enhance its growth strategy in the competitive landscape of mental health treatments?
With the recent $1 million investment in Axis Management Company, how does Brainsway Ltd Ord BRSYF foresee this partnership impacting its revenue streams and market access in the mental health sector?
What specific milestones does Brainsway Ltd Ord BRSYF have in place to evaluate the performance of its investment in Axis Integrated Mental Health, and how will these influence future funding decisions?
Considering the rapid achievement of revenue milestones by Axis, what strategic measures is Brainsway Ltd Ord BRSYF implementing to ensure sustained growth and expansion within the mental health treatment market?
**MWN-AI FAQ is based on asking OpenAI questions about Brainsway Ltd (OTC: BRSYF).
NASDAQ: BRSYF
BRSYF Trading
0.07% G/L:
$13.55 Last:
300 Volume:
$13.54 Open:
